The U.S. Senate on Wednesday confirmed Dr. Erica Schwartz as director of the Centers for Disease Control and Prevention (CDC), ending a nearly year-long leadership vacuum at the agency. The confirmation vote was 51-44, with Sen. Tim Kaine (D-VA) as the sole Democrat supporting her nomination. Six senators, including Sens. Ruben Gallego (D-AZ) and Ron Johnson (R-WI), did not vote.
Schwartz, a retired Navy rear admiral and former deputy surgeon general, will become the first Black woman to lead the CDC. She succeeds Dr. Jay Bhattacharya, who served as acting director since February 2026. The agency has operated without a permanent director since August 2025, when Susan Monarez was fired after 29 days in the role amid a dispute with Health Secretary Robert F. Kennedy Jr. over vaccine policy.
Public health challenges await Schwartz, who takes office as the CDC responds to record-high measles cases, a cyclosporiasis outbreak linked to contaminated lettuce, and an Ebola outbreak in Africa. She will also address rising vaccine hesitancy, which some experts attribute in part to recent policy changes and rhetoric.
Part 1: Immediate Action & Core Facts
The Senate’s confirmation of Schwartz follows a contentious confirmation hearing on July 15, 2026, where she faced questions about her stance on vaccines and her willingness to challenge Kennedy’s directives. Sen. Bill Cassidy (R-LA), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, pressed her on whether she would resist politically motivated health guidance. Schwartz stated she believed vaccines are safe and effective, including those using mRNA technology, which Kennedy has criticized.
Schwartz’s confirmation comes after Kennedy’s firing of Monarez in August 2025, which Monarez testified was due to her refusal to implement Kennedy’s vaccine recommendations, which she described as not based on science. Kennedy has stated he assisted in vetting Schwartz. A federal judge later blocked a 2026 vaccine schedule update proposed by Kennedy and the acting CDC director at the time, citing improper procedure in selecting advisory panel members. An appeal is ongoing.
Part 2: Deeper Dive & Context
Leadership and Controversy
Schwartz’s confirmation ends a period of instability at the CDC, which has seen multiple acting directors since Monarez’s ousting. Dr. Demetre Daskalakis, a former CDC official who resigned in August 2025, has noted the agency’s challenges, stating Schwartz will have significant work ahead. The CDC currently employs approximately 12,000 people, though staffing has been affected by layoffs and resignations during the second Trump administration.
During her confirmation hearing, Schwartz avoided directly addressing whether she would challenge Kennedy if he attempted to override her decisions. Sen. Bernie Sanders (I-VT) opposed her nomination, arguing she had not sufficiently distanced herself from Kennedy’s controversial stances. Sanders stated, “I think the American people are owed better than what President Trump has nominated.”
Public Health Priorities
Schwartz inherits a CDC facing multiple crises:
- Measles outbreaks: The U.S. has recorded its highest number of measles cases in 35 years, according to CDC data.
- Cyclosporiasis: A parasitic infection linked to contaminated produce has spread across the country, with health officials investigating outbreaks tied to shredded iceberg lettuce.
- Ebola response: The CDC is monitoring an ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda, though no cases have been reported in the U.S.
Public health experts have raised concerns that vaccine hesitancy has increased, partly due to recent policy changes and public statements. Some critics argue that Kennedy’s rhetoric and actions have contributed to this trend, though others note that broader societal factors also play a role.
Political and Institutional Context
Schwartz’s confirmation reflects a partisan divide in the Senate, with 50 Republicans and Sen. Kaine voting in favor and 43 Democrats and Independents opposing. The confirmation occurred nearly four months after the March 2026 deadline set by federal law for a permanent CDC director to be nominated.
Schwartz holds degrees in biomedical engineering, medicine, and law from Brown University and the University of Maryland. Her career includes roles as the Coast Guard’s chief medical officer and service in the U.S. Public Health Service Commissioned Corps. She previously led responses to Ebola and H1N1 outbreaks during her tenure in the Navy and federal health agencies.
Kennedy’s Role and Ongoing Disputes
Kennedy, who has been a vocal critic of certain vaccine policies, has stated he helped vet Schwartz. His tenure as health secretary has been marked by disputes with career scientists, including the firing of Monarez and the attempted implementation of a revised vaccine schedule. A federal judge ruled in spring 2026 that most members of the CDC’s vaccine advisory panel had been improperly selected, blocking the schedule update. The appeal process is ongoing.
Schwartz’s confirmation does not resolve the underlying tensions between Kennedy’s office and the CDC’s scientific leadership. During her hearing, she emphasized her belief in vaccines’ safety but did not commit to challenging Kennedy’s directives publicly. Sen. Cassidy, who initially questioned her resolve, ultimately voted to confirm her after additional discussions, stating he was confident she would make independent decisions.
What’s Next for the CDC?
As Schwartz begins her tenure, the CDC faces the dual challenge of addressing immediate public health threats while rebuilding trust in its vaccine recommendations. Her ability to navigate the agency’s internal and external pressures—particularly the influence of Kennedy’s office—will be closely watched. The agency’s response to the measles and cyclosporiasis outbreaks will serve as early indicators of her leadership.
Federal law requires the Trump administration to nominate a permanent CDC director by March 2026, a deadline that was missed before Schwartz’s nomination in April 2026.